Thiel G, Harder F, Loertscher R, Brünisholz M, Landmann J, Brunner F, Follat F, Wenk M, Mihatsch M
Transplant Proc. 1984 Oct;16(5):1187-90.
One hundred recipients of first cadaveric kidney transplants were treated with three different immunosuppressive regimens: (1) conventional immunosuppression, (2) CsA alone, and (3) low-dose CsA in combination with low-dose prednisone, with rapid adjustment to give CsA whole blood trough levels of 300 to 800 ng/mL. One-year graft survival in the aza + pred group was 76%, and in the CsA alone group 75%. Graft survival at two and six months in the CsA-pred group was 94%. The dose of CsA in the CsA-pred group in the first two months posttransplant was only about half that given to the CsA-alone group. Surprisingly, the reduction in the CsA dose also reduced the number of methylprednisolone pulses given for treating rejection by greater than 50%. The incidence of nephrotoxicity and extrarenal side effects also fell considerably. Withdrawal of prednisone in the CsA-pred group after five months led to reversible rejection in two cases. In conclusion, (1) the rapid reduction in the CsA dosage is beneficial and has no drawbacks, and (2) our guidelines for withdrawing prednisone (timing of withdrawal, rate of reduction in dosage) still need further refinement.
(1)传统免疫抑制;(2)单独使用环孢素(CsA);(3)低剂量CsA与低剂量泼尼松联合使用,并迅速调整剂量以使CsA全血谷浓度达到300至800 ng/mL。硫唑嘌呤+泼尼松组的一年移植肾存活率为76%,单独使用CsA组为75%。CsA-泼尼松组在术后两个月和六个月时的移植肾存活率为94%。CsA-泼尼松组在移植后前两个月的CsA剂量仅为单独使用CsA组的约一半。令人惊讶的是,CsA剂量的减少还使用于治疗排斥反应的甲泼尼龙冲击次数减少了50%以上。肾毒性和肾外副作用的发生率也大幅下降。CsA-泼尼松组在五个月后停用泼尼松导致两例可逆性排斥反应。总之,(1)CsA剂量的迅速减少是有益的且没有缺点,(2)我们关于停用泼尼松的指导原则(停药时间、剂量减少速率)仍需进一步完善。